RATIONALE: To enhance the effectiveness of antipsychotics in first-episode psychosis is crucial in order to achieve the most favourable prognosis. Difference in effectiveness between antipsychotics is still under debate. OBJECTIVE: The purpose of this study is to determine the long-term (3-year) effectiveness and efficacy of haloperidol, risperidone and olanzapine in first-episode schizophrenia-spectrum disorders. METHOD: This is a prospective, randomized, open-label study. Data for the present investigation were obtained from a large epidemiologic and 3-year longitudinal intervention programme of first-episode psychosis. One hundred seventy-four patients were randomly assigned to haloperidol (N = 56), olanzapine (N = 55), or risperidone (N = 63) and followed up for 3 years. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on per-protocol populations was conducted in the analysis for clinical efficacy. RESULTS: The treatment discontinuation rate for any cause differed significantly between treatment groups (χ (2) = 10.752; p = 0.005), with a higher rate in haloperidol than in risperidone and olanzapine. The difference in the discontinuation rate between risperidone and olanzapine showed a tendency towards significance (χ (2) = 3.022; p = 0.082). There was a significant difference in the mean time to all-cause discontinuation between groups (log-rank χ ( 2 ) = 12.657;df = 2; p = 0.002). There were no significant advantages to any of the three treatments in reducing the psychopathology severity. CONCLUSIONS: After 3 years of treatment, a lower effectiveness was observed in haloperidol compared to second-generation antipsychotics (SGAs). The use of SGAs for the treatment of early phases of nonaffective psychosis may enhance the effectiveness of antipsychotics.
RCT Entities:
RATIONALE: To enhance the effectiveness of antipsychotics in first-episode psychosis is crucial in order to achieve the most favourable prognosis. Difference in effectiveness between antipsychotics is still under debate. OBJECTIVE: The purpose of this study is to determine the long-term (3-year) effectiveness and efficacy of haloperidol, risperidone and olanzapine in first-episode schizophrenia-spectrum disorders. METHOD: This is a prospective, randomized, open-label study. Data for the present investigation were obtained from a large epidemiologic and 3-year longitudinal intervention programme of first-episode psychosis. One hundred seventy-four patients were randomly assigned to haloperidol (N = 56), olanzapine (N = 55), or risperidone (N = 63) and followed up for 3 years. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on per-protocol populations was conducted in the analysis for clinical efficacy. RESULTS: The treatment discontinuation rate for any cause differed significantly between treatment groups (χ (2) = 10.752; p = 0.005), with a higher rate in haloperidol than in risperidone and olanzapine. The difference in the discontinuation rate between risperidone and olanzapine showed a tendency towards significance (χ (2) = 3.022; p = 0.082). There was a significant difference in the mean time to all-cause discontinuation between groups (log-rank χ ( 2 ) = 12.657;df = 2; p = 0.002). There were no significant advantages to any of the three treatments in reducing the psychopathology severity. CONCLUSIONS: After 3 years of treatment, a lower effectiveness was observed in haloperidol compared to second-generation antipsychotics (SGAs). The use of SGAs for the treatment of early phases of nonaffective psychosis may enhance the effectiveness of antipsychotics.
Authors: John S March; Susan G Silva; Scott Compton; Mark Shapiro; Robert Califf; Ranga Krishnan Journal: Am J Psychiatry Date: 2005-05 Impact factor: 18.112
Authors: Nina Schooler; Jonathan Rabinowitz; Michael Davidson; Robin Emsley; Philip D Harvey; Lili Kopala; Patrick D McGorry; Ilse Van Hove; Marielle Eerdekens; Wim Swyzen; Goedele De Smedt Journal: Am J Psychiatry Date: 2005-05 Impact factor: 18.112
Authors: Wolfgang Gaebel; Mathias Riesbeck; Wolfgang Wölwer; Ansgar Klimke; Matthias Eickhoff; Martina von Wilmsdorff; Maria C Jockers-Scherübl; Kai-Uwe Kühn; Matthias Lemke; Andreas Bechdolf; Stefan Bender; Detlef Degner; Ralf Schlösser; Lutz G Schmidt; Andrea Schmitt; Markus Jäger; Gerd Buchkremer; Peter Falkai; Stefan Klingberg; Wolfgang Köpcke; Wolfgang Maier; Heinz Häfner; Christian Ohmann; Hans J Salize; Frank Schneider; Hans-Jürgen Möller Journal: J Clin Psychiatry Date: 2007-11 Impact factor: 4.384
Authors: Joseph P McEvoy; Jeffrey A Lieberman; Diana O Perkins; Robert M Hamer; Hongbin Gu; Arthur Lazarus; Dennis Sweitzer; Christina Olexy; Peter Weiden; Stephen D Strakowski Journal: Am J Psychiatry Date: 2007-07 Impact factor: 18.112
Authors: Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; John M Kane; Christoph U Correll Journal: World Psychiatry Date: 2019-06 Impact factor: 49.548
Authors: Benedicto Crespo-Facorro; Victor Ortiz-Garcia de la Foz; Ignacio Mata; Rosa Ayesa-Arriola; Paula Suarez-Pinilla; Elsa M Valdizan; Obdulia Martinez-Garcia; Rocío Pérez-Iglesias Journal: Psychopharmacology (Berl) Date: 2014-01 Impact factor: 4.530
Authors: Maria Juncal-Ruiz; Mariluz Ramirez-Bonilla; Jorge Gomez-Arnau; Victor Ortiz-Garcia de la Foz; Paula Suarez-Pinilla; Obdulia Martinez-Garcia; Karl David Neergaard; Rafael Tabares-Seisdedos; Benedicto Crespo-Facorro Journal: Psychopharmacology (Berl) Date: 2017-05-31 Impact factor: 4.530
Authors: Richard J Drake; Merete Nordentoft; Gillian Haddock; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; Stefan Leucht; Markus Leweke; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Iris E Sommer; René S Kahn; Shon W Lewis Journal: Schizophr Bull Date: 2015-03-05 Impact factor: 9.306
Authors: Richard Whale; Michael Harris; Gail Kavanagh; Vijitha Wickramasinghe; Christopher I Jones; Steven Marwaha; Ketan Jethwa; Nirmalan Ayadurai; Andrew Thompson Journal: BJPsych Open Date: 2016-10-10
Authors: Marcos Gómez-Revuelta; José María Pelayo-Terán; María Juncal-Ruiz; Víctor Ortiz-García de la Foz; Javier Vázquez-Bourgon; Ana González-Pinto; Benedicto Crespo-Facorro Journal: Int J Neuropsychopharmacol Date: 2018-12-01 Impact factor: 5.176